丹防胶囊对免疫性肝纤维化大鼠的干预作用  

Intervention effects of Dan-fang capsule in rats with hepatic fibrosis

作　　者：胡晓会[1] 吴君[1] 陆爽[1] 

机构地区：[1]贵州医科大学感染病学教研室,贵阳550004

出　　处：《中华医学杂志》2017年第35期2783-2788,共6页National Medical Journal of China

基　　金：基金项目：贵阳市科技计划项目（201120419）

摘　　要：目的探讨丹防胶囊对猪血清致大鼠肝纤维化的干预作用。方法健康雄性1周龄sD大鼠[体重（180±20）g]60只经适应性喂养后，随机分为6组，即正常组（A组）、模型组（B组）、复方鳖甲软肝片组（C组）、丹防胶囊高剂量组（D组）、丹防胶囊中剂量组（E组）、丹防胶囊低剂量组（F组），每组10只。除A组外，其余各组均采用腹腔注射无菌猪血清复制大鼠肝纤维化模型。造模的同时，D、E、F组分别给予丹防胶囊4．32、2．16、0．54g／kg灌胃，C组给予复方鳖甲软肝片（0．54g／kg）灌胃，每日1次，共12周。12周末股动脉放血处死大鼠，测定血清谷丙转氨酶（ALT）、谷草转氨酶（AST）、Ⅲ型前胶原N端肽（PⅢNP）；行肝组织病理学检查；检测肝脏组织α平滑肌肌动蛋白（α-SMA）、Ⅰ型胶原（COL-Ⅰ）、Ⅲ型胶原（COL-Ⅲ）的表达。多组比较采用单因素方差分析。结果B组血清中ALT、AST、PHINP水平和肝组织中α-SMA、COL-I、COL-Ⅲ蛋白表达均显著高于A组，差异有统计学意义[（68．3±3．4）比（51．5±6．3）U／L、（205±52）比（135±24）U／L、（3．1±1．4）比（1．6±0．6）μg/L和0．35±0．02比0．13±0．02、0．37±0．02比0．13±0．02、0．43±0．13比0．13±0．01，t=17．020、71．053、1．552、0．214、0．241、0．292，均P〈0．01]。病理检查显示B组肝纤维化程度高于A组；丹防胶囊各剂量组血清ALT、AST、PIllNP水平和肝组织中01．SMA、COL-I、COL．Ⅲ蛋白表达均明显低于B组，差异均有统计学意义（t=-58．232--0．104，均P〈0．01）。而丹防胶囊各剂量组肝纤维化程度亦明显低于B组，差异有统计学意义（Z=3．821、3．761、3．904，P〈0．05）。结论丹防胶囊对猪血清致大鼠肝纤维化有一定的预防保护作用。Objective To investigate the interventional effect of Dan-fang capsule on liver fibrosis in rats. Methods Sixty one-week aged male healthy SD rats [ weight （ 180 ± 20） g ] were randomly divided into normal control group （group A）, hepatic fibrosis model group （group B）, Fu-Fang-Bie-Jia-Ruan-Gan tablet group （ group C）, Dan-fang capsule groups at high, middle and low dose group （ group D, E, F, respectively）. Except for the normal control group, hepatic fibrosis was induced in other groups by intraperitoneal injection of porcine serum. Simultaneously, rats in Dan-fang capsule groups were administered by gavage with Dan-fang capsule at doses of 4. 32, 2. 16, 0. 54 g/kg, respectively. Rats in Fu-Fang-Bie-Jia- Ruan-Gan tablet group were orally administered by gavage with Fu-Fang-Bie-Jia-Ruan-Gan tablet （0. 54 g/kg） every day and the normal control group received saline alone. All rats were killed at the end of the 12th week. Serum alanine aminotransferase （ALT）, aspartate aminotransferase （AST） and Pill np clia （Pill NP） were measured in the groups. Pathology changes of hepatic tissue were evaluated by hematoxylin- eosin （HE） and Masson staining. The proteinic expressions of alpha-smooth muscle actin （ot-SMA）, collagen- I （ COL- I ） and collagen- Ⅲ （ COL- Ⅲ） were observed with the method of immunohistochemistry. Analysis of variance was applied when data were compared among groups. Results Compared with those in the group A, the levels of ALT, AST and PIIINP in serum and the expressions of α-SMA, COL- I and COL-Ill in liver tissues were significantly higher in group B [ （68.3 ±3.4） vs （51.5 ±6. 3） U/L, （205 ± 52） vs （135 ±24） U/L, （3.1 ± 1.4） vs （1.6 ±0.6） μg/L and 0. 35 ± 0. 02 vs 0. 13 ±0. 02, 0. 37 4- 0.02 vs0. 13 ±0.02, 0.43 ±0. 13 vs 0. 13 ±0.01, t =17.020,71.053,1.552,0.214,0.241,0.292, all P 〈 0. 01 ], and the degree of liver fibrosis significantly increased in group B than that in group A. Comparedwith those in gro

关 键 词：肝硬化 丹防胶囊 Α-平滑肌肌动蛋白 Ⅰ型胶原 Ⅲ型胶原 

分 类 号：R285.5[医药卫生—中药学]